HYH has been the topic of a number of research reports. Morgan Stanley downgraded shares of Halyard Health from an “equal weight” rating to an “underweight” rating and set a $27.00 price objective on the stock. in a research report on Monday, October 12th. Zacks Investment Research lowered shares of Halyard Health from a “buy” rating to a “strong sell” rating in a research note on Wednesday, October 14th. JMP Securities reiterated a “buy” rating on shares of Halyard Health in a research note on Wednesday, August 5th. Deutsche Bank initiated coverage on shares of Halyard Health in a report on Friday, September 11th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of Halyard Health in a report on Wednesday. They set a “buy” rating and a $38.00 price objective on the stock. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $36.25.
The company’s market cap is $1.57 billion. The stock’s 50-day moving average is $30.42 and its 200-day moving average is $34.99.
Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm earned $390 million during the quarter, compared to analyst estimates of $388 million. Halyard Health’s quarterly revenue was down 4.5% on a year-over-year basis. On average, analysts predict that Halyard Health Inc will post $2.06 EPS for the current year.
In related news, CEO Robert E. Abernathy bought 10,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $31.06 per share, for a total transaction of $310,600.00. Following the transaction, the chief executive officer now owns 80,043 shares of the company’s stock, valued at $2,486,135.58. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Halyard Health, Inc. seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company has two business segments: Surgical and Infection Prevention (NYSE:HYH) and Medical Devices. The Company’s S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections. S&IP’s product portfolio includes sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves. Medical Devices segment provides a portfolio of product offerings, including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes, focused on pain management and respiratory and digestive health.
This story was originally published by Putnam Standard (http://putnamstandard.com) and is the sole property of Putnam Standard. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://putnamstandard.com/2015/12/03/halyard-health-inc-hyh-sees-unusually-high-trading-volume/674390/
Halyard Health Inc (HYH) Sees Unusually-High Trading Volume
Keine Kommentare:
Kommentar veröffentlichen